Zaki Moin, MD
Psychiatry · Richmond, TXNPI 1740262823
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 845 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 11.8% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 845 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- AbbVie$1K
- Vanda Pharmaceuticals Inc.$1K
- Alkermes, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Bausch Health US, LLC$941
- plus $8K from 26 others
Across 15 payments — averaging $4287.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Hoffmann-la Roche Limited$39K
- Genentech, Inc.$17K
- Pfizer$9K
What the payments were for
- Food & beverage$15,67797%
- Education$4583%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 95 | $1,906 |
| AbbVie(2 entities) | 99 | $1,491 |
| Vanda Pharmaceuticals Inc. | 62 | $1,400 |
| Alkermes, Inc. | 59 | $1,366 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 59 | $1,286 |
| Bausch Health US, LLC | 55 | $941 |
| Teva Pharmaceuticals USA, Inc. | 32 | $872 |
| Corium, LLC | 44 | $731 |
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $694 |
| Johnson & Johnson | 36 | $674 |
| Neos Therapeutics, LP | 34 | $490 |
| Sunovion Pharmaceuticals Inc. | 33 | $483 |
| Axsome Therapeutics, Inc. | 23 | $477 |
| Lundbeck LLC | 22 | $472 |
| Ironshore Pharmaceuticals Inc. | 26 | $456 |
| Indivior Inc. | 18 | $362 |
| Noven Therapeutics, LLC | 16 | $297 |
| Supernus Pharmaceuticals, Inc. | 15 | $290 |
| Tris Pharma Inc | 13 | $251 |
| Eisai Inc. | 12 | $231 |
| E.r. Squibb & Sons, L.L.C. | 10 | $218 |
| Neurocrine Biosciences, Inc. | 9 | $207 |
| Adlon Therapeutics L.p. | 6 | $109 |
| Idorsia Pharmaceuticals US Inc | 5 | $93 |
| Merck | 6 | $80 |
| Shire North American Group Inc | 4 | $73 |
| Almatica Pharma LLC | 3 | $50 |
| Livanova USA, Inc. | 2 | $40 |
| Jazz Pharmaceuticals Inc. | 2 | $35 |
| Bioxcel Therapeutics, Inc. | 2 | $30 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Neuronetics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$1,000
- ARISTADA INITIO$250
How this compares
$16,135 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AristadaAripiprazole Lauroxil | 21 | $73,474 |
| Invega SustennaPaliperidone Palmitate | 30 | $68,545 |
| RexultiBrexpiprazole | 14 | $22,939 |
| Lurasidone Hcl | 22 | $19,480 |
| Aripiprazole | 107 | $8,464 |
| Quetiapine Fumarate | 351 | $6,900 |
| BelsomraSuvorexant | 11 | $4,969 |
| Divalproex Sodium ErDivalproex Sodium | 104 | $3,309 |
| Ziprasidone Hcl | 46 | $3,177 |
| Paliperidone ErPaliperidone | 18 | $3,055 |
| Hydroxyzine Hcl | 93 | $1,967 |
| Mirtazapine | 99 | $1,773 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 18 | $1,619 |
| Trazodone Hcl | 373 | $1,575 |
| Risperidone | 137 | $1,538 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Aristada | $1,366 | $73,47421 claims |
| Johnson & JohnsonInvega Sustenna | $674 | $68,54530 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,906 | $22,93914 claims |
| MerckBelsomra | $80 | $4,96911 claims |
| Almatica Pharma LLCSertraline Hcl | $50 | $972172 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Richmond
- Rakesh JainLake Jackson$7.2M
- Arvinder Pal WaliaAustin$2.5M
- Suresh SureddiPlano$2.2M
- Martin GuerreroEl Paso$2M
- Marty BennettAddison$1.8M
- Matthew BramsHouston$1.5M
- Vikram MehraKaty$1.2M
- Joel HolinerDallas$948K
- Frank ChenHouston$941K
- Alice MaoHouston$850K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.